keyword
https://read.qxmd.com/read/38652119/long-term-remission-after-upfront-autologous-hematopoietic-stem-cell-transplant-for-cd5-diffuse-large-b-cell-lymphoma
#1
JOURNAL ARTICLE
Yosuke Masamoto, Akira Honda, Aya Shinozaki-Ushiku, Tetsuo Ushiku, Mineo Kurokawa
CD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and nine did not, despite preserved organ function and response after induction therapy...
April 23, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38651850/mycosis-fungoides-with-large-cell-transformation-cd30-and-b-cell-chronic-lymphocytic-leukemia
#2
JOURNAL ARTICLE
Mikela Petković, Ivana Ilić, Ružica Jurakić Tončić, Ivo Radman-Livaja, Romana Čeović
Mycosis fugnoides (MF) is an indolent cutaneous T-cell lymphoma (CTLC) and is the most common of all cutaneous lymphomas. An increased risk for developing a second primary malignancy in patients with CTCL has been described in several studies, with a range from 1.04 to 2.4 (1-4). Caucasian males are at higher risk for MF development. MF is often diagnosed at ages between 55 and 67 years, and second malignancy usually occurs 5 or 6 years after the diagnosis of MF was established (5). The most common second primary malignancies include non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), lung carcinoma, bladder carcinoma, and melanoma...
December 2023: Acta Dermatovenerologica Croatica: ADC
https://read.qxmd.com/read/38651449/ophthalmic-manifestations-in-patients-with-blood-malignancies
#3
REVIEW
Costanza Rossi, Alessandro Buizza, Giuseppe Alessio, Massimiliano Borselli, Andrea Taloni, Adriano Carnevali, Giovanna Carnovale Scalzo, Andrea Lucisano, Vincenzo Scorcia, Giuseppe Giannaccare
Ocular complications can occur in up to 90% of patients with blood malignancies. Such complications range from direct infiltration to local hemostatic imbalance and treatment-related toxicity. This narrative review is based on a systematic computerized search of the literature conducted until January 2024 and examines the common ocular complications associated with blood cancers. Ocular complications from primary disease include mass effects from ocular adnexal lymphomas and intraocular lymphomas, with B-cell lymphomas accounting for 95% of primary ocular presentations...
March 28, 2024: Hematology Reports
https://read.qxmd.com/read/38650799/malignancy-associated-secondary-hemophagocytic-lymphohistiocytosis-mimicking-an-infection-a-case-report-and-review-of-the-literature
#4
Meenakshi Gopalakrishnan, Arunalini Ramanathan, Dhaarani Jayaraman, Sri Gayathri Shanmugam, Julius Xavier Scott
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hematological disorder of immune dysregulation associated with significant challenges in diagnosis and management. Described as primary HLH secondary to genetic defects or more commonly secondary to infections, it can also occur secondary to malignancy, i.e., malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH). A five-year-old male child presented with left cervical adenopathy and a high-spiking fever for two weeks. He had pallor, anasarca, multiple enlarged and matted cervical lymph nodes, respiratory distress, and hepatomegaly...
March 2024: Curēus
https://read.qxmd.com/read/38650415/-testicular-involvement-in-pediatric-lymphoid-tumors-a-review-of-the-literature-and-a-series-of-clinical-observation
#5
JOURNAL ARTICLE
S Korneeva M, A Batmanova N, R Panferova T, T Valiev T
Lymphoid tumors with testicular involvement in childhood are rare and heterogeneous. The disease may manifest with uni- or bilateral scrotal enlargement. Comprehensive examination includes evaluation of all lymph nodes involvement, as well as ultrasound examination, magnetic resonance imaging and positron emission tomography. A diagnosis is made on basis of morphological and immunohistochemical verification. Determination of lymphoid tumor variant and stage, is recommended to perform chemotherapy according to prognostic risk group, and, in some cases, transplantation of hematopoietic stem cells is required as consolidation therapy...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38645784/recent-advancements-in-hematopoietic-stem-cell-transplantation-in-taiwan
#6
REVIEW
Chi-Cheng Li, Xavier Cheng-Hong Tsai, Wei-Han Huang, Tso-Fu Wang
Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival...
2024: Tzu chi medical journal
https://read.qxmd.com/read/38638855/diverse-and-reprogrammable-mechanisms-of-malignant-cell-transformation-in-lymphocytes-pathogenetic-insights-and-translational-implications
#7
REVIEW
Mariusz A Wasik, Patricia M Kim, Reza Nejati
While normal B- and T-lymphocytes require antigenic ligands to become activated via their B- and T-cell receptors (BCR and TCR, respectively), B- and T-cell lymphomas show the broad spectrum of cell activation mechanisms regarding their dependence on BCR or TCR signaling, including loss of such dependence. These mechanisms are generally better understood and characterized for B-cell than for T-cell lymphomas. While some lymphomas, particularly the indolent, low-grade ones remain antigen-driven, other retain dependence on activation of their antigen receptors seemingly in an antigen-independent manner with activating mutations of the receptors playing a role...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38635938/clonal-hematopoiesis-and-therapy-related-myeloid-neoplasms-after-autologous-transplant-for-hodgkin-lymphoma
#8
JOURNAL ARTICLE
Chengcheng Yan, Melissa A Richard, Christopher J Gibson, Jianbo He, Alysia Bosworth, David K Crossman, Purnima Singh, Lindsey Hageman, Rashi Kalra, Saro H Armenian, Julie Vose, Daniel J Weisdorf, Benjamin L Ebert, Yutaka Yasui, Stephen J Forman, Ravi Bhatia, Smita Bhatia
PURPOSE: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS: We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71)...
April 18, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38634054/analysis-of-the-treatment-and-prognosis-of-266-cases-of-extranodal-natural-killer-t-cell-lymphoma-nasal-type-in-a-single-medical-center
#9
JOURNAL ARTICLE
Lei Yang, Liqiang Wei, Xin Li, Jia Cong, Jin Ye, Na Yao, Jing Yang, Liang Wang, Jingwen Wang
OBJECTIVE: To assess the impact of different treatment strategies and risk factors on the prognosis of patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL) in a single medical center. METHODS AND ANALYSIS: The clinical features of 266 patients with ENKTL were retrospectively analyzed, among whom those in stages I and II received sandwich therapy, while those in stages III and IV underwent chemotherapy plus autologous hematopoietic stem cell transplantation...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38633119/graft-versus-host-disease-after-autologous-stem-cell-transplantation-in-a-recipient-who-underwent-allogeneic-stem-cell-transplantation-20-years-earlier
#10
JOURNAL ARTICLE
Osamu Imataki, Shunsuke Yoshida, Tomoya Ishida, Haruyuki Fujita, Makiko Uemura
A literature review does not provide information about the safety of autologous hematopoietic stem cell transplantation (HSCT) in a recipient who has previously received allogeneic HSCT. We treated a 69-year-old woman with diffuse large B cell lymphoma. The patient received autologous stem cell transplantation (ASCT) in the second complete remission of malignant lymphoma. The patient had undergone allogeneic hematopoietic SCT (allo-HSCT) for chronic myeloid leukemia 20 years ago. Chronic myeloid leukemia had been in complete remission for the previous 20 years...
April 2024: EJHaem
https://read.qxmd.com/read/38631712/combinational-therapy-of-car-t-cell-and-hdt-asct-demonstrates-impressive-clinical-efficacy-and-improved-car-t-cell-behavior-in-relapsed-refractory-large-b-cell-lymphoma
#11
JOURNAL ARTICLE
Wei Liu, Hesong Zou, Lianting Chen, Wenyang Huang, Rui Lv, Yan Xu, Huimin Liu, Yin Shi, Kefei Wang, Yi Wang, Wenjie Xiong, Shuhui Deng, Shuhua Yi, Weiwei Sui, Guangxin Peng, Yueshen Ma, Huijun Wang, Lulu Lv, Jianxiang Wang, Jun Wei, Lugui Qiu, Wenting Zheng, Dehui Zou
BACKGROUND: Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and hematological stem cell infusion can promote adoptively transferred T-cell expansion, enhancing antitumor effects. Therefore, we conducted a phase I/II clinical trial in which CNCT19 (an anti-CD19 CAR T-cell) was administered after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) in patients with R/R LBCL...
April 16, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38630129/monocyte-to-platelets-ratio-mpr-at-diagnosis-is-associated-with-inferior-progression-free-survival-in-patients-with-mantle-cell-lymphoma-a-multi-center-real-life-survey
#12
JOURNAL ARTICLE
Andrea Duminuco, Alessandra Romano, Isacco Ferrarini, Gabriella Santuccio, Annalisa Chiarenza, Amalia Figuera, Laura Anastasia Caruso, Giovanna Motta, Giuseppe Alberto Palumbo, Carlo Mogno, Alessia Moioli, Francesco Di Raimondo, Carlo Visco
Mantle cell lymphoma (MCL) pathogenesis is strongly related to the role of the tumor immune microenvironment (TIME) in which MCL cells proliferate. TIME cells can produce growth signals influencing MCL cells' survival and exert an antitumoral immune response suppression. The activity of TIME cells might be mirrored by some ratios of peripheral blood cell subpopulations, such as the monocyte-to-platelet ratio (MPR). We reviewed the clinical features of 165 consecutive MCL patients newly diagnosed and not eligible for autologous stem cell transplantation (both for age or comorbidities) who accessed two Italian Centers between 2006 and 2020...
April 17, 2024: Annals of Hematology
https://read.qxmd.com/read/38629251/outcomes-of-the-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma-in-the-rituximab-era-a-population-based-study
#13
JOURNAL ARTICLE
Wenshuai Zheng, Mingjuan Liu, Lixun Guan, Shenyu Wang
BACKGROUND: Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a common complication of follicular lymphoma (FL) and is usually associated with a dismal outcome. However, the survival rate of these patients has improved over the last 20 years with the introduction of rituximab. This study aimed to access the outcome of transformation to DLBCL (t-DLBCL) from FL in a retrospective series that began after the widespread use of rituximab use. In addition, we also compared survival between t-DLBCL and primary DLBCL (p-DLBCL) in the same timeframe...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38628817/late-onset-familial-hemophagocytic-lymphohistiocytosis-in-a-survivor-of-hodgkin-s-lymphoma
#14
Mirza Rameez Samar, Daania Shoaib, Nida E Zehra, Munira Moosajee
Hemophagocytic Lymphohistiocytosis is an inflammatory condition which results in over activation of the immune system. It could be either sporadic or familial. The familial subtype is linked with various genetic mutations and is commonly a disease of the young. Here we report a case of HLH in an adult, occurring in the background of a successfully treated hematological malignancy. Upon workup, he was also found to have pathogenic STXBP2 mutation, suggesting HLH of familial origin. To date, only few cases of adult-onset familial HLH have been brought to light...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38628779/the-antiapoptotic-effects-of-conditioned-medium-from-bone-marrow-derived-mesenchymal-stromal-stem-cells-on-cyclophosphamide-induced-testicular-damage-in-rat-an-experimental-study
#15
JOURNAL ARTICLE
Zeynab Esmailpour, Soheila Madadi, Maryam Baazm
BACKGROUND: Cyclophosphamide (CP) has some negative effects on the reproductive system. Stem cells and their metabolites are being utilized to enhance fertility after chemotherapy. OBJECTIVE: This study aimed to investigate the impact of conditioned medium (CM) derived from bone marrow mesenchymal stromal stem cells (BM-MSCs) on the toxic effects of CP on testicles. MATERIALS AND METHODS: BM-MSCs were isolated, a CM was collected and 25-fold concentrated...
February 2024: International Journal of Reproductive Biomedicine (Yazd, Iran)
https://read.qxmd.com/read/38626450/covid-19-antibody-titers-after-tixagevimab-cilgavimab-injection-in-patients-with-hematologic-diseases-a-single-center-prospective-study
#16
JOURNAL ARTICLE
Naokazu Nakamura, Hiroko Tsunemine, Ryo Ikunari, Tomomi Sakai, Nobuyoshi Arima
Knowledge of the SARS-CoV-2 antibody titers induced by tixagevimab-cilgavimab in patients with hematologic diseases remains insufficient. Here, we performed a single-center, prospective study to reveal the changes in antibody titer after administration of tixagevimab-cilgavimab in 78 patients with hematologic diseases. The median peak titer was 155.4 U/mL, and the median AUC was 46556 days·U/mL. First, we compared several characteristics between patients with low titers (peak titer ≤ 155...
April 16, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38618727/efficacy-and-nuances-of-precision-molecular-engineering-for-hodgkin-s-disease-to-a-gene-therapeutic-approach
#17
JOURNAL ARTICLE
Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain
Gene therapy is a particularly useful treatment for nervous system genetic diseases, including those induced especially by infectious organisms and antigens, and is being utilized to treat Hodgkin's disease (HD). Due to the possible clonal relationship between both disorders, immunotherapy directed against CD20 positive cells may be a more effective treatment in patients with persistent HD and NHL. HL growth can be inhibited both in vitro and in vivo by AdsIL-13Ralpha2. High-dose treatment combined with stem cell transplantation has been effective in treating HIV-negative lymphoma that has progressed to high-risk or relapsed disease...
2024: Critical Reviews in Immunology
https://read.qxmd.com/read/38618451/a-rare-case-of-extranodal-natural-killer-t-cell-lymphoma-nasal-type-associated-with-hemophagocytic-lymphohistiocytosis-in-a-patient-with-recurrent-sinusitis
#18
Bryce R Christensen, Chung-Ting J Kou, Lauren E Lee
We present a rare case of hemophagocytic lymphohistiocytosis (HLH) secondary to nasal-type extranodal natural killer/T-cell lymphoma (ENKL). Nasal-type ENKL is a rare subtype of non-Hodgkin's lymphoma usually associated with Epstein-Barr virus (EBV). The patient was a 19-year-old woman who presented with facial numbness, diminished hearing, and dysgeusia. She was febrile with palatal necrosis, loss of gag reflex, and cranial nerve palsies. Labs revealed neutropenia. Broad-spectrum antimicrobials, including amphotericin, were started...
March 2024: Curēus
https://read.qxmd.com/read/38616634/-chimeric-antigen-receptor-t-cells-car-t-cells-therapy-for-b-cell-hematological-malignancies-from-the-israeli-society-of-hematology-and-transfusion-medicine
#19
JOURNAL ARTICLE
Uri Greenbaum, Dana Yehudai-Ofir, Ofrat Beyar Katz, Liat Shargian, Elad Jacoby, Sigal Grisaru, Tsila Zuckerman, Ron Ram, Abraham Avigdor
Using immunotherapy to fight cancer, and specifically, the use of engineered T-cells expressing a chimeric receptor against an antigen found on malignant cells (chimeric antigen receptor, CAR-T cells) constitutes a significant breakthrough in the treatment of the disease. In recent years, several CAR-T therapies have been approved in Europe and the USA, and some are already approved and funded through the national health basket in Israel, for the indications of diffuse large B-cell lymphoma, mantle cell lymphoma and B-cell acute lymphoblastic leukemia, after the failure of at least two lines of treatment...
April 2024: Harefuah
https://read.qxmd.com/read/38616351/post-transplant-cyclophosphamide-and-short-term-everolimus-as-graft-versus-host-prophylaxis-in-patients-with-relapsed-refractory-lymphoma-and-myeloma-final-results-of-the-phase-ii-octet-ever-trial
#20
JOURNAL ARTICLE
Tim Richardson, Christof Scheid, Marco Herling, Lukas P Frenzel, Carmen Herling, Marta Rebecca Cruz Aguilar, Sebastian Theurich, Michael Hallek, Udo Holtick
BACKGROUND: Conditioning regimens and the choice of immunosuppression have substantial impact on immune reconstitution after allogeneic hematopoietic stem cell transplantation (aHSCT). The pivotal mechanism to maintain remission is the induction of the graft-versus-tumor effect. Relapse as well as graft versus host disease remain common. Classic immunosuppressive strategies implementing calcineurin inhibitors (CNI) have significant toxicities, hamper the immune recovery, and reduce the anti-cancer immune response...
April 14, 2024: European Journal of Haematology
keyword
keyword
103609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.